Tier 1 — highest
N-acetylcysteine for patients with alcohol use disorder, post-traumatic stress disorder, and their co-occurrence: a systematic review of placebo-controlled randomized trials
BMC Psychiatry
2026
26(1):384
Bibliography
- PubMed
- PMID 42115982
- PubMed Central
- PMC13162469
- Funding
- Open-access funding was provided by the Science, Technology & Innovation Funding Authority (STDF) in cooperation with the Egyptian Knowledge Bank (EKB).
- Competing interests
- The authors declared no competing interests.
Study snapshot
| Design | Systematic review and meta-analysis of randomized placebo-controlled trials |
|---|---|
| Model | Human |
| Sample | 7 randomized double-blind placebo-controlled trials; 566 participants |
| Intervention | N-acetylcysteine versus placebo as an adjunct in alcohol use disorder, PTSD or co-occurring AUD/PTSD |
| Duration | Varied across included trials |
| Endpoints | Alcohol craving; PTSD severity; Alcohol use; Anxiety; Depression; Biomarkers |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified



